Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Zepbound (tirzepatide) for weight management Zepbound, Eli Lilly dual-action GLP-1/GIP agonist, faced similar restrictions
Gasmi A, et al
There's no strong research that shows that microdosing works well, and it isn't approved by the FDA, which means the agency hasn't reviewed it for safety
Should this dual-track coverage move forward, it would set a dangerous precedent other drugs could be added to the TRICARE-approved list but remain excluded from the TRICARE For Life coverage, weakening an earned benefit relied upon primarily by uniformed services retirees and their families
US$ 27.70
US$ 29.46
US$ 26.07
US$ 22.78
US$ 22.01
